Pfizer Inc. (NYSE:PFE) agreed to pay $325 million to settle a lawsuit brought by health-care benefit providers who claimed the drugmaker marketed the epilepsy drug Neurontin for unapproved uses. The settlement, which needs approval from a federal judge in Boston, would end a case over claims that the company’s Parke-Davis unit schemed to market the drug for unapproved conditions as early as 1994. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 0.75%. On last trading day company shares ended up $29.71. Analysts mean target price for the company is $34.45. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -2.17%.
A latest data on Bristol Myers Squibb Co (NYSE:BMY) melanoma medicine Yervoy, counting updated consequences from an attempt to unite it with an added potential cancer immunotherapy, propose it can perk up healing for patients with mutually advanced and somewhat previous stage sickness, according to conclusions out on Monday. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -1.31% in last trading session and ended the day on $49.09. BMY gross Margin is 72.40% and its return on assets is 8.00%.Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -7.59%.
Drugmaker Merck & Co. Inc. (NYSE:MRK) has a tablet for house dust mite allergies in final patient testing that could hit the market in two or three years, and it’s considering other therapies. Merck & Co., Inc. (NYSE:MRK) shares moved up 0.12% in last trading session and was closed at $57.93, while trading in range of $57.48 – $58.20. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 16.65%.
Johnson & Johnson (NYSE:JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (:LADD) immunotherapy platform. The deal has been facilitated by the Johnson & Johnson’s innovation center in California. Johnson & Johnson (NYSE:JNJ) ended the last trading day at $102.17. Company weekly volatility is calculated as 0.95% and price to cash ratio as 9.83.Johnson & Johnson (NYSE:JNJ) showed a positive weekly performance of 1.18%.
GreenGro Technologies, Inc. (OTCMKTS:GRNH) recently announced a progress update on the Anaheim Location of Vertical Hydrogarden following a successful soft launch in late March, where month over month revenues have realized an increase of 367 % taking the two stores over $140,000 in April. The company announced the acquisition in Q1 of 2014 and since has focused on key strategic management hires that would propel sales of not only the Anaheim Location but the Roseville location as well. Economies of scale have since been realized with the negotiation of new manufacturing and distribution agreements from preferred partners; optimized order processing and inventory fulfilment contracts; and optimized store redesigns that increase margins and profitability of each location. On last trading day company shares ended up $0.305.
Leave a Reply